PURPOSE: ILX23-7553 (1,25-dihydroxy-16-ene-23-yne vitamin D3) is a vitamin D analogue that was developed to avoid the hypercalcemia that may limit the use of vitamin D as an anti-cancer agent. We performed a phase I study of ILX23-7553 to determine its side-effect profile, pharmacokinetics, and to document any observed antitumor activity. PATIENTS AND METHODS: Adult patients with refractory solid tumors were enrolled. A modified Fibonacci dose escalation scheme was employed. ILX23-7553 was administered orally daily for three consecutive days, and repeated in 7-day cycles. Plasma drug concentrations were assayed by radioimmunoassay and radioreceptor assay. RESULTS: Sixteen patients were enrolled to 10 dose levels ranging from 1.7 to 37.3 μg/m(2)/day. The maximum tested dose was six times higher than the maximally-tolerated dose (MTD) in dogs. Dose-limiting toxicity was not observed. ILX23-7553 concentrations on cycle 1 day 1 of treatment were comparable to concentrations on cycle 2 day 1, suggesting limited accumulation. One patient with adrenal cortical cancer had stable disease for 23 weeks, but no objective responses were observed. CONCLUSIONS: ILX23-7553 was well tolerated at the doses tested, with no evidence of hypercalcemia. The plasma concentrations achieved were approximately 100-fold lower than those associated with tumor growth inhibition in vitro, limiting use of this formulation.
PURPOSE: ILX23-7553 (1,25-dihydroxy-16-ene-23-yne vitamin D3) is a vitamin D analogue that was developed to avoid the hypercalcemia that may limit the use of vitamin D as an anti-cancer agent. We performed a phase I study of ILX23-7553 to determine its side-effect profile, pharmacokinetics, and to document any observed antitumor activity. PATIENTS AND METHODS: Adult patients with refractory solid tumors were enrolled. A modified Fibonacci dose escalation scheme was employed. ILX23-7553 was administered orally daily for three consecutive days, and repeated in 7-day cycles. Plasma drug concentrations were assayed by radioimmunoassay and radioreceptor assay. RESULTS: Sixteen patients were enrolled to 10 dose levels ranging from 1.7 to 37.3 μg/m(2)/day. The maximum tested dose was six times higher than the maximally-tolerated dose (MTD) in dogs. Dose-limiting toxicity was not observed. ILX23-7553 concentrations on cycle 1 day 1 of treatment were comparable to concentrations on cycle 2 day 1, suggesting limited accumulation. One patient with adrenal cortical cancer had stable disease for 23 weeks, but no objective responses were observed. CONCLUSIONS: ILX23-7553 was well tolerated at the doses tested, with no evidence of hypercalcemia. The plasma concentrations achieved were approximately 100-fold lower than those associated with tumor growth inhibition in vitro, limiting use of this formulation.
Authors: Gary G Schwartz; M Craig Hall; Diana Stindt; Suzanne Patton; James Lovato; Frank M Torti Journal: Clin Cancer Res Date: 2005-12-15 Impact factor: 12.531
Authors: Z Bar-Shavit; S L Teitelbaum; P Reitsma; A Hall; L E Pegg; J Trial; A J Kahn Journal: Proc Natl Acad Sci U S A Date: 1983-10 Impact factor: 11.205
Authors: Josephia R Muindi; Candace S Johnson; Donald L Trump; Renee Christy; Kristie L Engler; Marwan G Fakih Journal: Cancer Chemother Pharmacol Date: 2009-04-26 Impact factor: 3.333
Authors: Preetpal S Sidhu; Nicholas Nassif; Megan M McCallum; Kelly Teske; Belaynesh Feleke; Nina Y Yuan; Premchendar Nandhikonda; James M Cook; Rakesh K Singh; Daniel D Bikle; Leggy A Arnold Journal: ACS Med Chem Lett Date: 2014-02-13 Impact factor: 4.345
Authors: Preetpal S Sidhu; Kelly Teske; Belaynesh Feleke; Nina Y Yuan; Margaret L Guthrie; Grant B Fernstrum; Nishita D Vyas; Lanlan Han; Joshua Preston; Jonathan W Bogart; Nicholas R Silvaggi; James M Cook; Rakesh K Singh; Daniel D Bikle; Leggy A Arnold Journal: Cancer Chemother Pharmacol Date: 2014-08-09 Impact factor: 3.333